Precure LLC has picked Helix to handle clinical whole genome and multiomics data from a million biospecimens. This marks a major step for precision medicine at Mayo Clinic and could reshape care across health systems.
Researchers at ICAR-Central Rice Research Institute have shown that Plant OpenCRISPR-1, an AI-designed genome editor, works as well as established systems for editing rice genes.
A failed Phase 3 trial does not always mean a drug is ineffective. Luca Pani of NetraMark argues that AI-driven patient selection could transform how clinical evidence is generated and interpreted.
Lōkahi Therapeutics is strengthening its collaboration with The University of Alabama’s Culverhouse College of Business, giving students direct experience in evaluating real biopharma assets through the ai² Pipeline division.
Artificial intelligence has crossed a threshold in biotechnology by designing functional viruses that target bacteria, opening vast opportunities and urgent responsibilities for India and the world.
OpenAI claims a breakthrough on a Millennium Prize problem as billions flow into AI and researchers warn about the risks of runaway systems. Genomics projects show AI’s potential for medicine, even as the industry faces tough questions about safety and oversight.
Stanford researchers built a virtual biotech company powered by 37,000 AI agents, which quickly identified promising drug targets and independently suggested a cancer therapy later validated by a major pharmaceutical company.
LSUA has broken new ground with the first accredited 90 credit hour accelerated bachelor's degrees in bioinformatics and information technology, offering students a faster and more focused route into high-demand STEM fields.
